Fosun Pharma
复星医药
Executive Summary
Fosun Pharma is one of China's largest pharmaceutical conglomerates with a diversified portfolio spanning drug discovery, manufacturing, and distribution. The company has an active business development strategy, particularly focused on in-licensing Western assets for the Chinese market and co-development partnerships. With clear BIOSECURE status, Fosun represents a relatively low-risk partner for US pharma companies seeking China market access. The company's strong financial position and established commercialization capabilities make it an attractive partner for licensing deals.
Structure: Fosun Pharma operates as a Hong Kong-listed holding company under the broader Fosun International conglomerate, with extensive subsidiary networks across pharmaceutical manufacturing, R&D, and distribution in China. The company likely utilizes traditional holding company structures rather than VIE arrangements given its pharmaceutical focus and Hong Kong listing. Due diligence should focus on subsidiary-level regulatory compliance and the complex web of related party transactions within the broader Fosun ecosystem.
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under any current or proposed restrictions
Key Exposures:
- •Potential future designation risk due to size and government connections
- •Complex subsidiary structure may contain unknown exposure points
Mitigation: No specific mitigation measures identified as company currently maintains clear status
BD Intelligence
Therapeutic Areas:
Recent Deals: Insufficient recent deal data available - recommend direct engagement to assess current partnership appetite
Approach: Approach through senior BD channels with focus on China market access partnerships and co-development opportunities. Company likely receptive to in-licensing discussions for innovative assets.
Red Flags
- ⚠Limited publicly available information on recent corporate activities
- ⚠Complex subsidiary structure requires thorough due diligence
- ⚠Broader Fosun Group connections may introduce additional compliance considerations
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.